Search results for " Targeted therapy"

showing 10 items of 198 documents

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

2021

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan&ndash

0301 basic medicinemedicine.medical_specialtyPrognostic factorobesityrenal cell carcinomaMultivariate analysisCabozantinibPrognosiClinical Biochemistrybody mass indexurologic and male genital diseasesGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineOverall survivalIn patientneoplasmsPathologicallcsh:R5-920real-world databusiness.industrybody mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapymedicine.diseasetargeted therapyfemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisprognosislcsh:Medicine (General)businessBody mass indexDiagnostics
researchProduct

Exosomal HSP60: a potentially useful biomarker for diagnosis, assessing prognosis, and monitoring response to treatment.

2017

Introduction: Cell-to-cell communication is imperative for life and it is mediated by sending and receiving information via the secretion and subsequent receptor-mediated detection of biological molecules. Exosomes (EXs) secreted from cells to the extracellular environment play an important role in intercellular communication in normal and pathological conditions. Areas covered: New evidence indicates that tumor cells-derived EXs contribute to cancer progression through the modulation of tumor microenvironment. The exosomal heat shock protein 60 (HSP60) is very likely a key player in intercellular cross-talk, particularly during the progress of diseases, such as cancer. Many studies have fo…

0301 basic medicinetheranostic2734BiologyExosomesPathology and Forensic Medicine03 medical and health sciencesExtracellular VesiclesImmune systemHeat shock proteinNeoplasmsGeneticsmedicineBiomarkers TumorAnimalsHumansMolecular Targeted TherapyLiquid biopsyExtracellular Vesicles (EVs)Molecular BiologyCancerTumor microenvironmentLiquid BiopsyExosomes (EXs)CancerChaperonin 60medicine.diseasePrognosisHeat Shock Protein 60 (HSP60)MicrovesiclesBiomarker030104 developmental biologyTreatment OutcomeImmunologyCancer researchMolecular MedicineHSP60BiomarkersExpert review of molecular diagnostics
researchProduct

Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape

2012

It is now well known that tumor immunosurveillance contributes to the control of cancer growth. Many mechanisms can be used by cancer cells to avoid the antitumor immune response. One such mechanism relies on the capacity of cancer cells or more generally of the tumor microenvironment to generate adenosine, a major molecule involved in antitumor T cell response suppression. Adenosine is generated by the dephosphorylation of extracellular ATP released by dying tumor cells. The conversion of ATP into adenosine is mediated by ectonucleotidase molecules, namely, CD73 and CD39. These molecules are frequently expressed in the tumor bed by a wide range of cells including tumor cells, regulatory T …

AdenosineStromal cellArticle SubjectHealth Toxicology and Mutagenesislcsh:Biotechnologylcsh:MedicineAntineoplastic AgentsBiologyPharmacology5'-nucleotidaseDephosphorylationImmune systemNeoplasmslcsh:TP248.13-248.65GeneticsmedicineAnimalsHumansEctonucleotidaseMolecular Targeted Therapy5'-NucleotidaseMolecular BiologyImmune EvasionTumor microenvironmentlcsh:RGeneral MedicineAdenosineCancer cellCancer researchMolecular MedicineResearch ArticleBiotechnologymedicine.drugJournal of Biomedicine and Biotechnology
researchProduct

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomis…

2017

Summary Background Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF V600 -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAF V600 -mutant melanoma. Methods COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a B…

AdultMaleProto-Oncogene Proteins B-raf0301 basic medicineOncologymedicine.medical_specialtySkin NeoplasmsTime FactorsPhases of clinical researchYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansMolecular Targeted TherapyProgression-free survivalVemurafenibMelanomaProtein Kinase InhibitorsAgedAged 80 and overSulfonamidesPerformance statusbusiness.industryMelanomaMEK inhibitorBinimetinibMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyVemurafenibOncologyTolerabilitychemistry030220 oncology & carcinogenesisMutationBenzimidazolesFemaleCarbamatesbusinessmedicine.drugThe Lancet Oncology
researchProduct

The emerging role of miRNA-132/212 cluster in neurologic and cardiovascular diseases: Neuroprotective role in cells with prolonged longevity

2021

Abstract miRNA-132/212 are small regulators of gene expression with a function that fulfills a vital function in diverse biological processes including neuroprotection of cells with prolonged longevity in neurons and the cardiovascular system. In neurons, miRNA-132 appears to be essential for controlling differentiation, development, and neural functioning. Indeed, it also universally promotes axon evolution, nervous migration, plasticity as well, it is suggested to be neuroprotective against neurodegenerative diseases. Moreover, miRNA-132/212 disorder leads to neural developmental perturbation, and the development of degenerative disorders covering Alzheimer’s, Parkinson’s, and epilepsy’s …

Agingmedicine.medical_specialtyNeurologyDegenerative Disordermedia_common.quotation_subjectNeuroprotection03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmicroRNAAnimalsHumansMedicineMyocytes CardiacMolecular Targeted TherapyAxonCellular SenescenceComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonNeurons0303 health sciencesbusiness.industryNeurodegenerationAutophagyLongevityNeurodegenerative Diseasesmedicine.diseaseNeuroprotection3. Good healthMicroRNAsmedicine.anatomical_structureGene Expression RegulationCardiovascular DiseasesbusinessNeuroscience030217 neurology & neurosurgeryDevelopmental Biology
researchProduct

Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling

2014

The generation of excessive amounts of reactive oxygen species (ROS) leads to cellular oxidative stress that underlies a variety of forms of hepatocyte injury and death including that from alcohol. Although ROS can induce cell damage through direct effects on cellular macromolecules, the injurious effects of ROS are mediated largely through changes in signal transduction pathways such as the mitogen-activated protein kinase c-Jun N-terminal kinase (JNK). In response to alcohol, hepatocytes have increased levels of the enzyme cytochrome P450 2E1 (CYP2E1) which generates an oxidant stress that promotes the development of alcoholic steatosis and liver injury. These effects are mediated in larg…

Alcoholic liver diseaseClinical BiochemistryReview ArticleMitogen-activated protein kinase kinasemedicine.disease_causeBiochemistryCytochrome P450 2E10302 clinical medicineMolecular Targeted TherapyMitogen-activated protein kinaseslcsh:QH301-705.5c-Jun N-terminal kinasechemistry.chemical_classificationTNF tumor necrosis factorlcsh:R5-9200303 health sciencesCell DeathCYP2E1 cytochrome P450 2E1Cytochrome P-450 CYP2E13. Good healthCell biologyPKD protein kinase DLiverJNK c-Jun N-terminal kinaseSab SH3 homology associated BTK binding protein030211 gastroenterology & hepatologySignal transductionlcsh:Medicine (General)MAP Kinase Signaling SystemAPAP acetaminophenMKK MAPK kinaseBiology03 medical and health sciencesROS reactive oxygen speciesPKC protein kinase CmedicineAnimalsHumansMAPKKK MAPK kinase kinaseProtein kinase ACell damage030304 developmental biologyReactive oxygen speciesMAP kinase kinase kinaseOrganic ChemistryJNK Mitogen-Activated Protein KinasesAlcoholic liver diseasemedicine.diseaseERK1/2 extracellular signal-regulated kinase 1/2Fatty Liverlcsh:Biology (General)chemistryOxidative stressNAFLD nonalcoholic fatty liver diseaseReactive Oxygen SpeciesMAPK mitogen-activated protein kinaseOxidative stressRedox Biology
researchProduct

Allogeneic stem cell transplantation for renal cell carcinoma

2011

Allogeneic hematopoietic stem cell transplantation from a compatible donor has been utilized as adoptive immunotherapy in metastatic, cytokine-refractory renal cell carcinoma (RCC). Since the year 2000, several investigators have established that RCC is susceptible to a graft-versus-tumor effect: they reported that patients with renal cancer may have partial or complete disease responses, in the 20-40% range, after allogeneic transplantation following a reduced-intensity regimen. However, transplant-related mortality is still high in the 10-20% range, and responses are rarely durable. Experimental evidence suggests that donor-derived T cells and natural killer cells are the main mediators o…

Allogeneic transplantationT-Lymphocytesmedicine.medical_treatmentAntineoplastic AgentsHematopoietic stem cell transplantationurologic and male genital diseasesMinor histocompatibility antigenHumansTransplantation HomologousMedicineCytotoxic T cellPharmacology (medical)Molecular Targeted TherapyNeoplasm MetastasisCarcinoma Renal Cellbusiness.industryHematopoietic Stem Cell TransplantationImmunotherapyCombined Modality TherapyKidney NeoplasmsTissue DonorsKiller Cells NaturalTransplantationOncologyImmunologyStem cellbusinessCD8Expert Review of Anticancer Therapy
researchProduct

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working grou…

2016

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the g…

AngiogenesisLeftAngiogenesis Inhibitors030204 cardiovascular system & hematologyVentricular Dysfunction Left0302 clinical medicinetyrosine kinase inhibitorNeoplasmstyrosine kinase inhibitorsVentricular DysfunctionMolecular Targeted TherapyEpidermal growth factor receptorSocieties Medicalangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitorABLbiologyDisease ManagementGeneral MedicineItalyCardiovascular DiseasesSupplement Submission030220 oncology & carcinogenesisangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiology; Cardiomyopathies; Cardiotoxicity; Heart Failure; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Ventricular Dysfunction Left; Disease ManagementPractice Guidelines as TopicCardiologyCardiology and Cardiovascular MedicineCardiomyopathiesmedicine.medical_specialtyCardiologyAntineoplastic AgentsRisk AssessmentQT interval03 medical and health sciencesGrowth factor receptorInternal medicineMedicalmedicineHumansMonitoring PhysiologicHeart FailureCardiotoxicitybusiness.industryCancerHER2/epidermal growth factor receptor 2medicine.diseaseangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular MedicineCardiotoxicityangiogenesis inhibitorHeart failurebiology.proteinbusinessSocietiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Antioxidant Pathways in Alzheimers Disease: Possibilities of Intervention

2011

Alzheimer's disease (AD) is closely related to the occurrence of oxidative stress. It was claimed that all pathophysiological mechanisms involved in the onset and progression of AD are related to oxidative stress. Thus, it is important to evaluate if there is oxidative stress as well as the mechanism by which this happens in AD patients as well as in animal models of AD. Extracellular plaques of amyloid b peptides (Aβ), a hallmark of the disease, have been postulated to be more protective than damaging in terms of oxidative stress because they may be chemical sinks in which heavy metals are placed. More than a decade ago we reasoned that damage due to Ab might be caused not by extracellular…

AntioxidantAmyloidmedicine.medical_treatmentRespiratory chainNerve Tissue ProteinsBiologyPharmacologymedicine.disease_causeAntioxidantsAlzheimer DiseaseDrug DiscoverymedicineExtracellularAnimalsHumansMolecular Targeted TherapyPharmacologychemistry.chemical_classificationReactive oxygen speciesEstradiolVitamin Emedicine.diseaseUp-RegulationOxidative StressNeuroprotective AgentschemistryDietary SupplementsImmunologyAlzheimer's diseaseReactive Oxygen SpeciesOxidative stressCurrent Pharmaceutical Design
researchProduct